Stay updated with breaking news from Cipla Q3. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cipla Q3 PAT dips 2.6 per cent at Rs 729 crore : Rashtra News #Cipla #PAT #dips #cent #crore The Mumbai-based company had posted a consolidated profit after tax (PAT) of Rs 748 crore in the October-December quarter of 2020-21 fiscal. Drug major Cipla on Tuesday reported a 2.6 per cent decline in its consolidated
Hamied will continue to remain associated with the company as a non-executive director who is liable to retire by rotation.
Cipla also clocked in its highest ever quarterly revenue for the North America business, driven by strong respiratory season.
Gains in Nifty Pharma were driven by industry major Cipla, which soared over 6 percent following its strong quarterly performance. The stock also happens to be the top gainer on the Nifty 50.
Cipla's Q3 revenue for the quarter grew 13.7% YoY to Rs 6,604 crore, compared to Rs 5,810 crore in the same quarter last year. However, the drugmaker saw a marginal decline from the previous quarter's revenue of Rs 6,678 crore. Meanwhile, its EBITDA surged 24.2% YoY to Rs 1,748 crore in the December quarter of FY24.